We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lombard Med.Tec | LMT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 188.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 188.50 | 188.50 |
| Top Posts |
|---|
Posted at 30/4/2014 07:02 by skinny London, UK, 29 April, 2014 - On 26 February 2014, Lombard Medical (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair of abdominal aortic aneurysms, announced that it had published a circular which set out the Board of Directors' recommendations to, inter alia, reorganise the Lombard Medical Group pursuant to a Court approved scheme of arrangement (the "Scheme") so that Lombard Medical becomes a directly-owned subsidiary of Lombard Medical, Inc ("LM, Inc"). The Court Hearing, adjourned from 14 April 2014, was held today and the Scheme has been approved.On 25 April 2014 the Company announced the suspension of the Company's shares from trading on AIM. In addition, on the 25 April, LM, Inc. announced the pricing of the IPO of LM, Inc shares on the NASDAQ Global Market. LM, Inc shares commenced trading on the NASDAQ Global Market on 25 April. The Scheme is expected to become effective tomorrow morning, 30 April 2014, following delivery of the Court Order to the Registrar of Companies for registration. At 7.00 a.m. BST (2.00 a.m. ET) tomorrow shares in Lombard Medical, will be cancelled on AIM. This press release and the information it contains is not for publication or distribution, directly or indirectly, in or into the United States. This press release is not intended to, and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. -Ends- |
Posted at 25/4/2014 20:48 by nod 1.60 takes LMT (EVAR) back to its 12 month low. This is now a huge 30% to 40% below the original price range set by the advisors. Markets have not fallen anything like 30%~40% so the low price is not down to the market falling.This listing was a mess. The advisors were poor throughout. It looks like they gave LMT an inflated price to get the listing on their books. Like dodgy estate agents. Once again, the only winners have been the financial advisors.What has been the cost of this listing?This will appear in the Final Results as exceptionals but it is real money gone.Hopefully in the long run Nasdaq will be a better place for remaining shareholders. It may take a year or two though. |
Posted at 25/4/2014 08:42 by skinny London, UK, 25 April, 2014- On 26 February 2014, Lombard Medical (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair of abdominal aortic aneurysms, announced that it had published a circular which set out the Board of Directors' recommendations to, inter alia, reorganise the Lombard Medical Technologies Group pursuant to a Court approved scheme of arrangement (the "Scheme") so that Lombard Medical becomes a directly-owned subsidiary of Lombard Medical, Inc ("LM, Inc").Earlier today, LM, Inc. announced the pricing of the initial public offering on the NASDAQ Global Market of 5,000,000 ordinary shares at a price to the public of $11 per share, raising $55 million. In addition, LM, Inc. has granted the underwriters a 30-day option to purchase up to an additional 750,000 ordinary shares from LM, Inc. Ahead of the Court Hearing to approve the Scheme, scheduled to take place on Tuesday 29 April 2014, shares in the Company will be suspended from trading on AIM from 7.30 a.m. BST today. Following Court approval, the Scheme is expected to become effective on 30 April 2014 and trading in shares in the Company will be cancelled on AIM at 7.00 a.m. BST (2.00 a.m. ET). Shares in LM, Inc. are expected to commence trading on the NASDAQ Global Market at 2.30 p.m. BST (9.30 a.m. ET) on 30 April 2014. This press release and the information it contains is not for publication or distribution, directly or indirectly, in or into the United States. This press release is not intended to, and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. -Ends- |
Posted at 06/3/2014 21:35 by nod I fully agree with all those posts today - it's not a level playing field and the PIs get shafted all the time. This is common across the LSE these days as all companies are using the same set of brokers with the same greedy mentality and disregard for PIs.I've been complaining about this on PTEC where a placing of 45 million shares (326 million quid) is limited to institutions and their mates and directors. Fortunately in many of these situations the share price tends to fall close to the listing price and often below it as many instis sell quickly to make a quick buck. So PIs will often get a chance to buy close to the issue price or maybe below it.In the case of LMT, I think the move to Nasdaq will be beneficial and greatly increase interest and liquidity in the shares. I'm happy to hold these as LMT is finally selling products and prospects look brighter than ever.I decided not to add as I thought the share price may become volatile ahead of the delisting on London and a lower price may be possible before d-day. |
Posted at 06/3/2014 16:25 by stable I have been in Lmt for years, and intend to keep current holdings, but, recent events have shown that company and house broker have no interest in small stock holder as they are forced to do what the big boys want to doI am sure that all those large holders know so much more than we do and one of those details is the price that is going to be used when new money is raised in the US of A. Also I believe the Japaneses news that was until recently expected 1 st quarter this year has been delayed to suit LMT so that after we go to Nasdq there will be an announcement giving a boost to the shareprice and all those very lucky us holders. The volume recently seen does not justify a 12.5 percent fall without some prior knowledge. Perhaps I am letting my imagination grow but I will stay until something makes me feel differently, but it does not stop me feel that I have been taken over a barrell and been f.....d. |
Posted at 06/3/2014 13:27 by munkychunky The share price moves so much as the market for LMT is not very liquid. I am of the opinion that the IIs already invested would have had first refusal with regard to taking part in any placing - thats just my opinion - I don't know...Since the announcement of the move to aim there had always been included in the news releases disclosure with regard to further financing, but the first time I've seen figures mentioned was in the publication of the circular. |
Posted at 15/2/2014 00:43 by nod I am very tempted to add some shares ahead of the Nasdaq IPO. It looks as if the share price is just waiting for the move. LMT probably want to be in a position to present some good sales news in the IPO document. |
Posted at 30/1/2014 08:18 by nod A good story today...30 January 2014Lombard Medical Technologies PLCLive case demonstration using Aorfix at LINC 2014London, UK and Irvine, CA, 30 January, 2014 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic aneurysms ("AAAs"), announces that yesterday a team of surgeons, led by Dr. Andrej Schmidt, Oberarzt (Senior Physician) Angiologie, Leipzig Park-Krankenhaus, successfully performed a live case demonstration of a challenging AAA repair using Aorfix, the Company's flexible endovascular stent graft, to over 500 physicians at the 2014 Leipzig Interventional Course (LINC), Leipziger Messe, Leipzig, Germany.Prior to the live case Dr Schmidt demonstrated the Company's new simulation technology, developed in conjunction with Simbionix USA Corporation, which uses a patient CT scan to allow physicians to practice the procedure on a simulation of that patient's particular AAA anatomy ahead of the actual surgery. During the procedure, which was broadcast live from Park Hospital Leipzig, a panel of prominent vascular surgeons, interventional radiologists and interventional cardiologists, chaired by Professor Vicente Riambau, Professor and Chief of Vascular Surgery, Hospital Clinic of Barcelona, gave a series of presentations discussing their experiences of Aorfix in complex AAA anatomy. |
Posted at 08/1/2014 08:27 by nod Is the decision to de-list from London and move to Nasdaq designed to make a sale to a US company more straightforward?The reason is not an obvious one. They are currently expanding manufacturing in Didcot suggesting a long term commitment to UK manufacturing, yet de-listing from London.Are they simply disillusioned with the lack of interest from UK investors.I'm happy to move to Nasdaq - I suspect there will be more interest in LMT from US investors. It will also be good if the USD rises against the GBP. |
Posted at 20/11/2013 21:14 by nod Raymond Cohen was appointed as non-exec Chairman of LMT on 10 July 2013 to help LMT execute its strategy. What was interesting and a bit unusual was that John Rush the former Chairman of LMT for two years has stayed on as a non-exec director. This indicates Cohen was brought in for his very specific skills. To find a buyer and execute the sale probably. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
